R&D expense · Fiscal year 2025
| 1 | MerckMRK | $15.8B |
|---|---|---|
| 2 | AstraZenecaAZN | $14.2B |
| 3 | Eli LillyLLY | $13.3B |
| 4 | PfizerPFE | $10.4B |
| 5 | Bristol Myers SquibbBMY | $10.0B |
| 6 | GSKGSK | $9.9B |
| 7 | AbbVieABBV | $9.1B |
| 8 | Novo Nordisk A SNVO | $7.9B |
| 9 | AmgenAMGN | $7.3B |
| 10 | Regeneron PharmaceuticalsREGN | $5.9B |